论文部分内容阅读
本文报道了血清中甲状腺刺激抗体(TSAb)不能测出时,是否为突眼性甲状腺肿停止抗甲状腺药物治疗的最理想时机。 对象及方法:受试者为56例未经治疗TSAb阳性的突眼性甲状腺肿患者,其中女性40例,平均年龄41(18～67)岁。 治疗及随访:全部病例均用甲亢平治疗,开始为40mg/d,其后减量维持正常甲状腺机能状态。治疗中每3月随访1次,停药后每半年随访1次,共2年。随访包括体检及测定T_3、T_4、TSH及TSAb的血清浓度。按常规治疗期为18个月,如TSAb不能测出则较早停药。
This article reports on the optimal timing of antithyroid drugs to be stopped by athyroid goiter when serum thyroid stimulating antibody (TSAb) can not be detected. PARTICIPANTS AND METHODS: The subjects were 56 untreated TSAb-positive patients with exophthalmiasis, 40 of whom were women, with an average age of 41 (18-67) years. Treatment and follow-up: All cases were treated with hyperthyroidism, the beginning of 40mg / d, then reduced to maintain normal thyroid functional status. Treatment was followed up every 3 months, after stopping every half-year follow-up 1, a total of 2 years. Follow-up included physical examination and serum concentrations of T_3, T_4, TSH and TSAb. By conventional treatment period of 18 months, such as TSAb can not be measured earlier withdrawal.